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Objective: Peripheral arterial disease (PAD) is a commonmanifestation of systemic atherosclerosis. Apart from traditional
cardiovascular risk factors, several novel biologic mediators and genetic predisposing factors appear relevant in
determining the atherogenetic process leading to PAD. Genes encoding for renin angiotensin system (RAS) components
have been proposed as candidate in atherosclerosis. This study investigated four polymorphisms in angiotensinogen
(AGT), angiotensin converting enzyme (ACE), and angiotensin II receptor type 1 (AGTR1), genes of RAS, in both
predicting PAD and modulating the severity of the disease.
Methods: The ACE I/D and -240A>T, AGTM235T, and AGTR1 1166A>C polymorphisms were analyzed in 281 PAD
patients and in 485 controls comparable for age and sex.
Results: The ACED and -240T alleles both significantly influenced the predisposition to PAD. TheACED, but not -240
T, allele remained associated with PAD after Bonferroni correction (P  .004) and adjustment for cardiovascular risk
factors (P .03). The ACED allele influenced PAD predisposition with a dose-dependent effect (odds ratio for ACE ID
vs II genotype, 1.77; P  .006; ACE DD vs II genotype, 2.15; P  .001). The haplotype reconstruction analysis for the
ACE gene showed that the D/-240T haplotype significantly and independently influenced the predisposition to PAD
(P  .02). In 190 PAD patients with no additional atherosclerotic localizations (isolated PAD), a significant association
between ACED and -240T alleles and PAD was observed. Only the ACED allele remained associated with isolated PAD
after Bonferroni correction (P  .02) and after adjustment for cardiovascular risk factors (P  .02). The haplotype
reconstruction analysis for the ACE gene showed that the D/-240T, but not the D/-240A haplotype significantly
influenced the predisposition to PAD (P  .0003). No influence of the polymorphisms analyzed on the severity of the
disease, according to Rutherford categories, was found.
Conclusions: The present study contributes data to highlight the role of the ACED/-240T haplotype in predisposing to
PAD, also in the absence of other atherosclerotic comorbidities. ( J Vasc Surg 2009;50:1399-404.)Peripheral arterial disease (PAD) is a common manifes-
tation of systemic atherosclerosis and is associated with an
increased risk of cardiovascular events related to the coex-
istence of coronary artery disease (CAD) and cerebrovascu-
lar disease (CVD).1 Apart from traditional cardiovascular
risk factors, several novel biologic mediators and genetic
predisposing factors appear relevant in determining the
atherogenetic process that leads to PAD.1-3 PAD is indeed
a complex disorder. Its pathogenesis is the result of the
interaction between multiple genes and multiple environ-
mental factors and is not yet completely defined. However,
information is increasing on the relevance of investigating
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doi:10.1016/j.jvs.2009.07.075polymorphisms in candidate genes, such as renin angioten-
sin system (RAS) genes and the methylenetetrahydrofolate
reductase (MTHFR) gene. These genes are involved in
homocysteine metabolism and their association with the
predisposition to PAD has been demonstrated.2,3
The involvement of the RAS in atherosclerosis has been
demonstrated,4 and genes encoding for its components, such
as angiotensinogen (AGT), angiotensin-converting enzyme
(ACE), and angiotensin II receptor type 1 (AGTR1), have
been proposed as candidates that influence the predisposi-
tion to both CAD and CVD.5,6 The few published reports
on the relationship between RAS genes and PAD have had
conflicting results.2,7,8 A recent hypothesis is that people
carrying susceptibility polymorphisms in RAS genes might
exhibit higher angiotensin II levels, which may be crucial in
the development of the disease.
The M235T polymorphism in the AGT gene, which
consists of a nucleotide substitution in exon 2 that leads to
themethionine¡ threonine substitution at position 235 in
the amino acid sequence, is associated with increased con-
centrations of angiotensinogen in circulating blood.9 It has
been speculated that increased plasma or tissue angio-
tensinogen level associated with the AGT 235T variant may
stem from alterations in different steps of the metabolic
pathway, which could lead to a small increase in baseline
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tion of the AGT M235T polymorphism with hypertension9
and myocardial infarction10 has been demonstrated.
In the intron 16 of the gene encoding for ACE, a
polymorphism consisting of an insertion/deletion (I/D) of
a 287-bp fragment has been identified,11 and the ACE D
allele has been reported to be associated with increased
serum levels of the circulating enzyme.11 The ACE DD
genotype is associated with higher plasma levels of the
enzyme, the II genotype with lower ACE levels, and the ID
genotype with intermediate levels. Experimental studies
have reported a functional role for the ACE I/D polymor-
phism in modulating angiotensin II levels12 as well as an
increased messenger RNA (mRNA) expression in white
blood cells from individuals carrying the ACE D allele
compared with those carrying the I allele.13
The role of the ACE I/D polymorphism in affecting
atherosclerosis is of interest. We have previously demon-
strated that the ACE D allele represents a susceptibility
factor not only for CAD14 but also for other atherosclerotic
localizations such as abdominal aortic aneurysm (AAA).15
Other functional polymorphisms in the promoter re-
gion of the ACE gene (-240AT) and in the gene encod-
ing for angiotensin II type 1 receptor (AGTR1 A1166C)
have been analyzed in atherosclerotic cardiovascular dis-
ease,16 and the AGTR1 polymorphism has been demon-
strated to influence aortic stiffness17 and vascular reacti-
vity,18 but no data are available concerning their role in PAD.
Because PAD is a complex disorder in which environ-
mental and genetic components interact in determining its
pathogenesis, we investigated the genetic influence of
four polymorphisms in RAS genes—ACE, AGT, and
AGTR1—as predisposing factors to PAD and as markers
potentially involved in the modulation of the severity of
the disease.
METHODS
Study population. We studied 281 patients with
symptoms or signs suggestive for the presence of PAD who
were referred to the Unit of Vascular Surgery of the Uni-
versity of Florence to be evaluated for possible surgical
intervention, in part analyzed in a previous study.19 This is
a retrospective case-control association study. PAD was
diagnosed when patients had typical symptoms of intermit-
tent claudication, such as cramping pain of the calves or
buttocks during exercise, and an ankle-brachial index at rest
of0.90, calculated according to the recommendations of
the American Heart Association.20
All patients were also evaluated for atherosclerotic dis-
ease at other locations. In particular, all patients underwent
a cardiologic evaluation that included an electrocardiogram
and echocardiogram. In patients with symptoms poten-
tially related to ischemic heart disease, additional studies
included echocardiogram with drug-induced stress testing,
myocardial scintigraphy, and coronary angiography. Ca-
rotid artery duplex ultrasound scanning with color-coded
echo flow imaging was also done. Patients with associated
familial and inflammatory AAAs were excluded from thestudy. Rutherford categories was assigned as follow: class 2,
moderate claudication; class 3, severe claudication; class 4,
rest pain; class 5 to 6, ulcers or gangrene.
The patients were compared with 485 clinically healthy
volunteers recruited from the staff of the University of
Florence and the hospital, and from partners or friends of
patients. The control group was selected to be comparable
for age and sex with the patient group. As part of a physical
examination, expert physicians performed a detailed inter-
view addressing personal and familial history to identify
disease-free controls and to exclude individuals who were
suspected of having any form of vascular disease.
The participants were considered to have hypertension
if they had been diagnosed as being hypertensive according
to the guidelines of European Society of Hypertension/
European Society of Cardiology21 or were taking antihy-
pertensive drugs. Dyslipidemia was defined according to
the Third Report of the National Cholesterol Education
Program (NCEP),22 and diabetes in agreement with the
American Diabetes Association.23 A positive family history
was defined as the presence of at least one first-degree
relative in whom cardiovascular disease had developed age
55 years for men and 65 years for women. All partici-
pants gave informed consent. The study complies with the
Declaration of Helsinki and was approved by the local
ethics committee.
Detection of RAS polymorphisms. Genomic DNA
extraction was performed from peripheral blood leucocytes
by using a QIAmp Blood Kit (QIAGEN, Hilden, Ger-
many).
Previously reported methods14,24 were used to geno-
type the following RAS polymorphisms:
● ACE I/D (rs4340; NT_010783.14:g.20217903_
20217904ins5),
● ACE -240AT(rs4291;NT_010783.14:g.20206205T
A),
● AGTR1 1166AC (rs5186; NT_005612.15:g.
54955134AC), and
● AGT M235T (rs699; NT_004559.13:g.7047947AG).
Statistical analysis. Statistical analysis was performed
with SPSS 11.5 software (SPSS Inc, Chicago, Ill). Contin-
uous variables are expressed as median (range). The non-
parametric Mann-Whitney test for unpaired data was used
for comparison between single groups, as appropriate. The
2 test was used to test for deviation of genotype distribu-
tion from Hardy-Weinberg equilibrium, to evaluate the
differences in genotype distribution and allele frequency,
and to analyze the prevalence of traditional risk factors
between patients and controls.
Logistic regression was used to analyze the association
between ACE, AGTR1, and AGT polymorphisms and
PAD under a dominant genetic model of inheritance that
compares individuals with one or more polymorphic alleles
with a baseline group with no polymorphic alleles (eg ACE
DDID vs II). The number of participants studied was
sufficient to detect, with a statistical power of 80% ( 0.8)
and significance at  0.05, absolute differences in ACE D
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P  .05 was considered to indicate statistical significance.
The Bonferroni correction was used for multiple test-
ing (the four candidate polymorphisms were treated as four
independent statistical tests) by multiplying the nominal P
value of each test by the number of tests conducted.
Haplotype reconstruction and frequency estimation
were performed using the R (http://www.r-project.org)
package haplo.stats by Expectation-Maximization strategy
(EM algorithm).25 The haplo.stats package was also used
to identify statistically significant associations between hap-
lotypes and disease risks by means of generalized linear
models.
RESULTS
Demographic and clinical characteristics of the study
populations are described in Table I. No deviation from the
expected genotype proportion predicted by the Hardy-
Weinberg equilibrium was observed for any of the poly-
morphisms analyzed.
The difference in genotype distribution for ACE I/D
and -240AT polymorphisms between PAD patients and
controls was significant. A significantly higher prevalence
for ACE D, but not -240T allele, in PAD patients was
found compared with the healthy volunteers. No signifi-
cant differences in genotype distribution and allele fre-
quency were observed for the other polymorphisms inves-
tigated (Table II).
The ACE D and -240T alleles both significantly influ-
enced the predisposition to PAD, even if, after Bonferroni
correction for multiple testing, only the ACE D allele
remained significantly associated with PAD (Table III).
The ACE D allele influenced PAD predisposition with a
Table I. Demographic and clinical characteristics of the
study populations
Variable
Patients (n 281) Controls (n 485)
P
Mean (range),
No. (%)
Mean (range),
No. (%)
Age, y 72 (30-93) 71 (24-95) .4
Males 220 (78) 360 (74) .2
Hypertension 167 (59.4) 99 (20) .0001
Diabetes 47 (16.7) 25 (5.2) .0001
Dyslipidemia 135 (48) 96 (19.8) .0001
Smoking habit 176 (62.6) 102 (21) .0001
Family historya 56 (19.9) 29 (5.9) .0001
CAD 70 (24.9) . . . . . .
AAA 34 (12.1) . . . . . .
CVD 28 (10.0) . . . . . .
Rutherford
category
2 28 (9.9) . . . . . .
3 188 (66.9) . . . . . .
4 48 (17.1) . . . . . .
5-6 17 (6.0) . . . . . .
AAA, Abdominal aortic aneurism; CAD, coronary artery disease; CVD,
cerebrovascular disease.
aFamily history of cardiovascular disease.dose-dependent effect, with odds ratios (ORs) of 1.77 forID vs II (95% confidence interval (CI), 1.18-2.67; P 
.006) and 2.15 for DD vs II (95% CI, 1.38-3.45; P 
.001), whereas no dose-dependent effect of the ACE
-240T allele was observed. After adjustment for age, sex,
and traditional risk factors, only the ACE D allele signifi-
cantly and independently affected the susceptibility to PAD
Table II. Genotype distribution and allele frequencies of
ACE, AGT, and AGTR1 gene polymorphisms of the
study populations
Genotype Allele
Patients
(n  281)
Controls
(n  485)
PNo. (%) No. (%)
ACE
DD 94 (33.5) 127 (26.2) . . .
ID 146 (52.0) 239 (49.3) . . .
II 41 (14.6) 119 (24.5) .003
D 0.59 0.51 .001
-240TT 46 (16.4) 80 (16.5) . . .
-240AT 146 (52.0) 211 (43.5) . . .
-240AA 89 (31.7) 194 (40.0) .048
-240T 0.42 0.38 .1
AGT
235TT 55 (19.6) 78 (16.1) . . .
235MT 133 (47.3) 240 (49.5) . . .
235MM 93 (33.1) 167 (34.4) .3
235T 0.43 0.41 .5
AGTR1
1166CC 19 (6.8) 31 (6.4) . . .
1166AC 104 (37.0) 210 (43.3) . . .
1166AA 158 (56.2) 244 (50.3) .2
1166C 0.25 0.28 .2
ACE, Angiotensin converting enzyme; AGT, angiotensinogen; AGTR1,
angiotensin II receptor type 1.
Table III. Univariate and multivariate analysis for ACE,
AGT and AGTR1 gene polymorphisms and susceptibility
to peripheral arterial disease
Analysis OR (95% CI) Pa
Univariate analysis
Age 1.02 (0.98-1.02) .06
Sex 0.80 (0.56-1.13) .2
Hypertension 6.08 (4.38-8.45) .0001
Smoking habit 8.06 (5.71-11.32) .0001
Diabetes 9.15 (3.57-23.44) .0001
Dyslipidemia 2.79 (1.98-3.93) .0001
ACE D 1.90 (1.29-2.81) .001b
ACE-240T 1.44 (1.05-1.96) .02b
AGT 235T 1.06 (0.78-1.45) .7
AGTR1 1166C 0.79 (0.59-1.06) .1
Multivariate analysisc
ACE D 2.13 (1.09-4.19) .03
ACE, Angiotensin converting enzyme; AGT, angiotensinogen; AGTR1,
angiotensin II receptor type 1; CI, Confidence interval; OR, odds ratio.
aValues of P  .05 are significant.
bBonferroni correction for multiple testing assessed by multiplying the
nominal P value of each test by 4 (ie, the number of genetic tests conducted):
ACE D, P  .004; ACE -240T, P  .08.
cAdjusted for age, sex, and traditional cardiovascular risk factors.(Table III). The haplotype reconstruction analysis for the
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haplotype significantly and independently influenced the
predisposition to PAD (Table IV).
No significant association between AGT M235T and
AGTR1 1166AC polymorphisms and PAD was found
(Table III).
We investigated the role of the ACE I/D polymor-
phism according to hypertension. The ACE D allele prev-
alence was the same in both hypertensive and normotensive
patients (D  0.59), whereas the ACE D allele prevalence
was higher, even if not significantly, in hypertensive than in
normotensive controls (D 0.53 vs 0.49; P .3; Table V).
No difference was observed in genotype distribution
for all the polymorphisms analyzed, according to Ruther-
ford categories (Table VI).
When we examined 190 of 281 PAD patients (67.6%)
with no additional atherosclerotic localizations (isolated
PAD), we observed a significant association between PAD
and the ACE D (OR, 1.88; 95% CI, 1.20-2.95; P  .006)
and -240T alleles (OR, 1.56; 95% CI, 1.09-2.23; P .02).
The ACE D allele remained significantly associated with
isolated PAD after Bonferroni correction for multiple test-
ing (P  .02) and after adjustment for age, sex, and
cardiovascular risk factors (OR, 2.29; 95% CI, 1.14-4.61;
P  .02. The haplotype reconstruction analysis for ACE
gene showed that the D/-240T haplotype significantly
influenced the predisposition to PAD (coefficient, 0.08
[standard error, 0.03]; P  .0003).
No significant association between AGT M235T and
AGTR1 1166AC polymorphisms and isolated PAD was
found (P  .05).
DISCUSSION
Only a limited number of studies have investigated the
possible role of genetic components in the predisposition
to PAD, and all the available studies have assessed one or
just few genetic polymorphisms in candidate genes. The
Table IV. Haplotype reconstruction analysis for ACE
gene and analysis of association with peripheral arterial
disease by using the generalized linear model
Gene Haplotypea
Frequency
Coefficient SE PPAD Controls
ACE I-A 0.383 0.381 . . . . . . . . .
D-A 0.193 0.237 0.026 0.035 .5
D-T 0.401 0.272 0.082 0.029 .005
I-T 0.023 0.111 0.160 0.046 .0005
Generalized linear model adjusted for cardiovascular
traditional risk factors
ACE I-A 0.383 0.381 . . . . . . . . .
D-A 0.193 0.237 0.0004 0.035 .9
D-T 0.401 0.272 0.066 0.029 .02
I-T 0.023 0.111 0.127 0.052 .01
ACE, Angiotensin converting enzyme; PAD, peripheral arterial disease.
aACE gene polymorphisms: I/D and -240AT; I-A reference haplotype.present study has evaluated the influence of four polymor-phisms in candidate genes (ACE, AGT, AGTR1) as predis-
posing factors to PAD and has provided evidence that the
ACE D allele represents the main modulator of the suscep-
tibility to PAD, also in the absence of other atherosclerotic
comorbidities, and that the ACE -240T allele has an ancil-
lary role in predisposing to the disease. Indeed, the role of
the ACE -240T allele is evidenced only when ACE D allele
is present, such as in patients carrying the ACE D/-240T
haplotype.
An association of the ACE D/-240T haplotype with
the predisposition to the disease has also been demon-
strated in PAD patients without other atherosclerotic co-
morbidities. No association between the polymorphisms
investigated in AGT and AGTR1 genes and PAD was
observed.
Evidence from experimental and clinical studies shows
that the RAS, through its active peptide angiotensin II, may
contribute to the development and progression of athero-
sclerosis. The data document an association between can-
didate genes in RAS and CAD, AAA, and CVD,5,6,26
whereas few data are available concerning PAD.2,7,8,27
Findings from the present study support that theACE gene
and particularly the ACE I/D polymorphism modulates
the predisposition to PAD independently of traditional risk
factors.
Moreover, our results provide evidence that this poly-
morphism influences the susceptibility to the disease also in
the absence of other atherosclerotic localizations. The rel-
evance of this last finding might be explained by increased
angiotensin II levels, which are primarily modulated by the
ACE I/D polymorphism and in turn affect the atheroscle-
rotic process independently of the clinical expression of the
disease.
Among polymorphisms in RAS candidate genes, ACE
I/D and -240AT polymorphisms are of interest due to
their functional roles, and the mechanisms underlying the
apparent association between the ACE gene and athero-
sclerosis are intriguing. The ACE I/D polymorphism is
known to be responsible for 47% of the total phenotypic
variance of serum ACE,11 even though data derived from
an in vitro assay suggested that theACE intron 16 sequence
by itself had no effect in regulating transcription.28 This
result might suggest that ACE level variability is referred to
another locus in linkage disequilibrium with the I/D poly-
morphism. Actually, experimental data from ACE gene
expression analysis evidenced that the ACE D allele was
associated with higher ACE mRNA levels.12
The other polymorphism in the promoter region of the
ACE gene, the ACE -240AT SNP, previously investi-
gated in cardiovascular disease, has been demonstrated to
account for 14% of the variability in ACE levels.16
The current case-control study is in keeping with Basar
et al7 but is at variance with data from Renner et al8 on the
ACE I/D polymorphism. Even if ACE I/D genotype
distribution and allele frequency in the healthy individuals
from the present study were similar to those observed by
Renner et al,8 the conflicting results may be due to the
different sample size and clinical characteristics of patients,
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and hypertension.
To search for the influence of other RAS candidate
genes, apart from the ACE gene, on the atherosclerotic
process leading to PAD, we have investigated in this study,
for the first time to our knowledge, the role of the AGTR1
and AGT genes and showed no relationship with the dis-
ease. Data from our previous studies demonstrated a role
for the AGTR1 1166AC polymorphism in influencing
CAD,14 but not AAA disease.15 Positive and negative re-
sults have been reported regarding AGTR1 gene polymor-
phisms in cardiovascular disease or various intermediate
phenotypes, such as hypertension and intima media thick-
ness.17,29 Moreover, a recent meta-analysis of the AGT
M235T polymorphism and cardiovascular risk suggests an
overall weak association.30 The role of the AGT gene has
been also investigated in CVD and in PAD with conflicting
results.2,31 Therefore, data from association studies indi-
Table V. ACE I/D polymorphism genotype distribution
hypertension
ACE ID polymorphism
Hypertensive, No. (
PAD, group A Co
(n  167)
Genotype distribution
DD 56 (33.5)
ID 86 (51.5)
II 25 (15.0)
ACE D allele frequency 0.59a
ACE, Angiotensin converting enzyme; PAD, peripheral arterial disease.
aP  0.1 for ACE D allele frequency: group A vs group B.
bP  .007 for ACE D allele frequency: group C vs group D.
Table VI. Genotype distribution of ACE, AGT and
AGTR1 gene polymorphisms according to Rutherford
categories
Genotype
Rutherford category, No. (%)
P2 3 4 5-6
ACE gene
DD 11 (55.0) 59 (32.8) 13 (32.5) 2 (22.2) . . .
ID 5 (25.0) 97 (53.9) 20 (50.0) 7 (77.8) . . .
II 4 (20.0) 24 (13.3) 7 (17.5) . . . .1
-240TT 7 (35.0) 24 (13.3) 7 (17.5) 3 (33.3) . . .
-240AT 7 (35.0) 105 (58.3) 19 (47.5) 3 (33.3) . . .
-240AA 6 (30.0) 51 (31.7) 14 (35.0) 3 (33.3) .1
AGT gene
235TT 5 (25.0) 30 (16.7) 11 (27.5) 5 (55.6) . . .
235MT 8 (40.0) 93 (51.7) 16 (40.0) 2 (22.2) . . .
235MM 7 (35.0) 57 (31.7) 13 (32.5) 2 (22.2) .4
AGTR1 gene
1166CC 2 (10.0) 10 (5.6) 6 (15.0) . . . . . .
1166AC 7 (35.0) 73 (40.6) 14 (35.0) 3 (33.3) . . .
1166AA 11 (55.0) 97 (53.9) 20 (50.0) 6 (66.7) .4
ACE, Angiotensin converting enzyme; AGT, angiotensinogen; AGTR1,
angiotensin II receptor type 1.cate an effect of the ACE gene in all localizations ofatherosclerotic process, whereas AGT and AGTR1 genes
have been found to be related to coronary localization but
not in extracoronary districts.
The second end point of this study was the evaluation of
the influence of the polymorphisms investigated on the sever-
ity of the disease according to Rutherford categories. Our
findings did not demonstrate a relationship between all the
polymorphisms investigated and Rutherford categories, in
keeping with results from Renner et al.8 To the best of our
knowledge, no data are available on the role of all the other
polymorphisms analyzed in this study in modulating PAD
severity.
Our study has several limitations. Themain limitation is
related to the fact that we were not able to performDoppler
examination with ankle-brachial index measurement as well
as diagnostic procedures to evaluate asymptomatic athero-
sclerotic lesions in controls. A percentage of individuals
with PAD are clinically asymptomatic, thus the possibility
that our control group participants were disease-free can-
not be excluded. Moreover, we did not provide informa-
tion of the ACE phenotype. Some polymorphisms such as
ACE I/D and -240AT have functional effects on the
gene product,11,12,16,28 thus influencing angiotensin II
levels and in turn modulating the atherosclerotic process.
CONCLUSIONS
The present study, which shows a role forACED/-240T
haplotype in predisposing to PAD, apart from traditional
cardiovascular risk factors and other atherosclerotic localiza-
tions, may contribute to identify susceptibility markers in
candidate genes able to better define the pathophysiologic
mechanisms leading to the atherosclerotic process.
The increasing information on genetic factors involved
in atherosclerosis and in its clinical expression might con-
tribute to the development of further treatment strategies
and pharmacogenetics studies. Indeed, a beneficial effect of
ACE inhibitors therapy in improving walking time in PAD
patients has been demonstrated,32 and it has been sug-
gested that ACE inhibition has the potential to reduce the
incidence of cardiovascular events in PAD.33 Moreover,
pharmacogenetics studies demonstrated a different re-
allele frequency in patients and controls, according to
Normotensive, No. (%)
, group B PAD, group C Controls, group D
99) (n  114) (n  386)
2.3) 38 (33.3) 94 (24.3)
0.4) 58 (50.9) 188 (48.7)
7.3) 18 (15.8) 104 (26.9)
53 0.59b 0.49and
%)
ntrols
(n 
32 (3
40 (4
27 (2
0.sponse to ACE inhibitors related to ACE I/D polymor-
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conflicting results.35 Therefore, results from long-term and
properly designed prospective studies might contribute to
perform a pharmacogenetically tailored therapy.
We thank Alberto Magi for his contribution to the
statistical analysis.
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